COVID-19 vaccination produces a more consistent immune response than a past infection. With the delta variant, the difference in protection may be even greater.
Academic rigour, journalistic flair
Articles on COVID-19 variants
Displaying 61 - 80 of 133 articles
New Zealand will have to vaccinate 80-85% to reach population immunity. Until then, a blanket border re-opening, even if only for vaccinated people, would pose a high risk of new outbreaks.
New Zealand health authorities were quick to react to the threat of a COVID-19 outbreak and managed to avoid community transmission, but the unique nature of how the virus spreads also played a role.
Pressure is mounting to reopen the Canada-U.S. border, but there are risks. How well those risks are managed may be the difference between pandemic recovery or a fourth wave of COVID-19.
South Africa didn’t engage early enough with pharmaceutical companies in bilateral discussions to ensure it could get vaccines early.
New Zealand has avoided a COVID-19 outbreak, despite a visit by an Australian traveller with the delta variant. But now is clearly the time to introduce mandatory scanning and mask rules.
The Delta variant: What it is, where it came from, why it’s different and whether COVID-19 vaccines can prevent it.
We recently heard reports of a new and dangerous ‘hybrid’ variant circulating in Vietnam. There is such as a thing as a hybrid viral variant — but this doesn’t appear to be it.
It is unlikely that we will reach full herd immunity for COVID-19. However, we are likely to reach a practical kind of herd immunity through vaccination.
Bat hosts, lab leaks – tracing SARS-CoV-2 to its origins involves more than just tracking down patient zero.
Both the AstraZeneca and Pfizer vaccines still work relatively well against it — though only after the second dose.
The World Health Organization has created more memorable and less stigmatising names for coronavirus variants.
The COVID-19 variant responsible for Victoria’s latest outbreak is one of three Indian variant sub-types, which spreads more easily than the original strain. Here’s what we know so far.
One of the main fears regarding new SARS-CoV-2 variants is that they might be resistant to immunity granted by vaccines, including RNA vaccines.
Variants of interest and variants of concern seem to be popping up at an alarming rate. But how many of them do we really need to worry about?
What does the Seychelles experience tell us about variants, vaccine efficacy and herd immunity?
As the Indian variant becomes more prevalent within our borders, anti-South Asian sentiment is also growing, putting the community at a higher risk of hate crimes.
A viral immunologist answers key questions about the B16172 variant.
There’s still a lot we don’t know about the latest variant of concern: B16172.
Despite some public virtue signalling, the Canadian government is not doing all it can to improve global access to COVID-19 vaccines. Canada has yet to announce its position on the WTO patent waiver.
Job Board
-
Deputy Social Media Producer
-
Research Fellow /Senior Research Fellow – Implementation Science
-
Associate Professor, Occupational Therapy
-
GRAINS RESEARCH AND DEVELOPMENT CORPORATION CHAIRPERSON
-
Faculty of Law - Academic Appointment Opportunities
Top contributors
-
Professor in Applied Mathematics, University of Canterbury
-
Professor of Microbial Evolution at The Milner Centre for Evolution, University of Bath
-
Professor, Biochemistry, Trinity College Dublin
-
Professor of Physics, University of Auckland, Waipapa Taumata Rau
-
Senior Lecturer, The University of Queensland
-
Director: KRISP - KwaZulu-Natal Research and Innovation Sequencing Platform, University of KwaZulu-Natal
-
Professor, Biology, York University, Canada
-
Senior Lecturer, University of Auckland, Waipapa Taumata Rau
-
Professor of Public Health, University of Otago
-
Professor of Public Health, University of Otago
-
Early Career Research Leader, Emerging Viruses, Inflammation and Therapeutics Group, Menzies Health Institute Queensland, Griffith University
-
Dean Faculty of Health Sciences and Professor of Vaccinology at University of the Witwatersrand; and Director of the SAMRC Vaccines and Infectious Diseases Analytics Research Unit, University of the Witwatersrand
-
Instructor of Human Immunology, Emory University
-
Research Leader in Virology and Infectious Disease, Griffith University
-
Professor of Epidemiology, Medicine, and Infectious Diseases and Microbiology, University of Pittsburgh
